The longtime quest of one Microsoft data scientist to stop infant crib deaths has grown into a genomics and AI research program with lofty goals.
The firm said that with the approval, the firm's liquid biopsy-based ExoDx Prostate IntelliScore (EPI) test is now available in every state.
The TATTON study found a combination therapy could treat some EGFR-positive lung cancer patients who developed MET-based resistance, but the best way to gauge MET status isn't yet clear.
The MammaSeq assay comprises 79 genes and 1,369 mutations in breast cancer that could be used as potential downstream therapeutic targets.
OncoDNA anticipates a strong increase in the use of OncoDNA profiling products in Europe with the partnerships with Gammaray and AMS.
The company also published a study describing ImmRay PanCan-D biomarker signature that it said could be used to detect early-stage pancreatic cancer.
KMPJM will provide diagnostic and prognostic testing services based on genes, proteins, and other molecules to aid physicians in assessing and treating patients.
The researchers distinguished histologic subtypes of appendiceal cancer and confirmed that it is distinct from colorectal and other GI cancers.
PavMed subsidiary Lucid will commercialize Case Western's EsoCheck technology to detect Barrett's esophagus, a precursor to esophageal cancer.
PavMed subsidiary Lucid Diagnostics secured exclusive global rights to develop and commercialize genetic biomarker-based diagnostic tests using EsoCheck technology.
A man has confessed to the rape and murder of developmental biologist Suzanne Eaton, according to the New York Times.
The Irish Times reports that US lawmakers and law enforcement agencies are concerned about ties between the US and Chinese genomics firms.
Parents of children with spinal muscular atrophy tell the Washington Post they are pushing to get insurance coverage of Novartis's Zolgensma.
In PNAS this week: gene mutations in individuals with syndromic craniosynostosis, putative colorectal cancer drivers, and more.